<< Вернуться к списку статей журнала

Том 23 №1 - Приложение 2021 год - Нефрология и диализ

Современная концепция хронической болезни почек при ВИЧ-инфекции

Волгина Г.В. Томилина Н.А. Гаджикулиева М.М.

DOI: 10.28996/2618-9801-2021-1suppl-11-31

Аннотация: Распространенность инфицирования вирусом иммунодефицита человека (ВИЧ) приняла характер пандемии. Антиретровирусная терапия (АРТ) заметно снизила смертность от синдрома приобретенного иммунодефицита и оппортунистических инфекционных заболеваний, что привело к увеличению продолжительности жизни людей, инфицированных ВИЧ, но при этом увеличилась частота хронической болезни почек (ХБП), осложняющей ВИЧ-инфекцию. ХБП является сопутствующей патологией, имеющей большое клиническое значение среди людей, живущих с ВИЧ (ЛЖВ), и связана со значительной заболеваемостью и смертностью. Этиология заболеваний почек среди ЛЖВ включает заболевания, связанные с ВИЧ, такие как классическая нефропатия, ассоциированная с ВИЧ, или иммунокомплексные заболевания, ХБП, связанную с неинфекционной сопутствующей патологией (НСП) и антиретровирусной токсичностью. Хотя уже давно признано, что ВИЧ-инфекция является фактором риска ХБП, важно отметить, что характер заболевания почек у ЛЖВ изменился. Вместо ранее наблюдавшихся ВИЧ-ассоциированных заболеваний почек или острого повреждения почек, связанных с такими заболеваниями как оппортунистические инфекции, в настоящее время ХБП часто связана с НСП. Факторы риска развития ХБП у ВИЧ-инфицированных лиц включают старение, артериальную гипертензию, сахарный диабет, ко-инфекцию вирусом гепатита С, низкое количество клеток CD4, высокую вирусную нагрузку и ряд других. Все большее значение в мониторинге ЛЖВ приобретает кумулятивный токсический эффект АРТ, действие которой может привести к повреждению нескольких органов, в том числе и почек, следствием чего может быть значительное снижение качества жизни инфицированных лиц. ХБП также связана с увеличением госпитализации, особенно у пожилых пациентов и пациентов с коморбидной сердечно-сосудистой патологией. ХБП, однажды установленная, часто неуклонно прогрессирует и может привести к терминальной стадии почечной недостаточности, вероятность развития которой в 2-20 раз выше, чем у населения в целом. Выявление пациентов с факторами риска ХБП и соответствующий скрининг для раннего выявления ХБП имеют жизненно важное значение для улучшения результатов лечения пациентов. ВИЧ-инфекция и ХБП являются двумя эпидемическими заболеваниями с важными социальными, клиническими и экономическими последствиями. Взаимодействие между этими двумя болезнями представляет собой пересечение между инфекционными и неинфекционными заболеваниями. Этот обзор литературы предназначен для оценки современной проблемы, связанной с ХБП у лиц, живущих с вирусной инфекцией.

Для цитирования: Волгина Г.В., Томилина Н.А., Гаджикулиева М.М. Современная концепция хронической болезни почек при ВИЧ-инфекции. Нефрология и диализ. 2021. 23(1):11-31. doi: 10.28996/2618-9801-2021-1suppl-11-31

Весь текст

Ключевые слова: вирус иммунодефицита человека, хроническая болезнь почек, эпидемиология, факторы риска, антиретровирусная терапия, human immunodeficiency virus, chronic kidney disease, epidemiology, risk factors, antiretroviral therapy

Список литературы:

1. WHO. Data and Statistics. Available online: http://www.who.int/hiv/data/en/ (accessed on 9 July 2019).
2. ФНПЦ по профилактике и борьбе со СПИДом при Центральном НИИ эпидемиологии Роспотребнадзора: https://vademec.ru/news/2020/02/26/rospotrebnadzor-v-2019-godu-ot-vich-assotsiirovannykh-zabolevaniy-umerli-33-6-tysyachi-rossiyan/
3. Deeks S.G., Lewin S.R., Havlir D.V. The end of AIDS: HIV infection as a chronic disease. Lancet. 2013; 382, 1525-1533.
4. Maartens G., Celum C., Lewin S.R. HIV infection: epidemiology, pathogenesis, treatment, and prevention. Lancet. 2014;384, 258-271.
5. Samji H., Cescon A., Hogg R.S. et al. North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of IeDEA. Closing the gap increases in life expectancy among treated HIV-positive individuals in the United States and Canada. PLoS One. 2013; 8(12): e813-55. doi: 10.1371/journal.pone.0081355.
6. Hou J., Nast C.C. Changing concepts of HIV infection and renal disease. Curr Opinion Nephrol and Hypertens. 2018; 27(3):144-152. doi: 10.1097/MNH.0000000000000400
7. Antiretroviral Therapy Cohort Collaboration. Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies. Lancet HIV. 2017; 4:e349-e356.
8. Lohse N., Obel N. Update of Survival for Persons with HIV Infection in Denmark. Ann Intern Med. 2016; 165:749-750.
9. Gueler A., Moser A., Calmy A. et al. Swiss HIV Cohort Study, Swiss National Cohort. Life expectancy in HIV-positive persons in Switzerland: Matched comparison with general population. AIDS Lond. Engl. 2017; 31: 427-436. doi: 10.1097/QAD.0000000000001335.
10. Liyanage T., Ninomiya T., Jha V. et al. Worldwide access to treatment for end-stage kidney disease: a systematic review. The Lancet. 2015; 385(9981):1975-82.
11. Ando M., Yanagisawa N. Epidemiology, clinical characteristics, and management of chronic kidney disease in human immunodeficiency virus infected patients. World J Nephrol. 2015; 4(3): 388-395. DOI: http://dx.doi.org/10.5527/wjn.v4.i3.388
12. Milburn J., Jones R., Levy J.B. Renal effect of novel antiretroviral drugs. Nephrol Dial Transplant. 2017; 32:434-439.
13. Achhra A.C., Nugent M., Mocroft A., Ryom L., Wyatt C.M. Chronic Kidney disease and antiretroviral therapy in HIV-positive individuals: Recent developments. Curr HIV/AIDS Rep. 2016; 13:149-157.
14. Rosenberg A.Z., Naicker S., Levey A.S. et al. HIV-associated nephropathies: epidemiology, pathology, mechanisms and treatment. Nature Reviews Nephrology. 2015; 11(3):150-60.
15. Shlipak M.G., Wassel Fyr C.L., Chertow G.M. et al. Cystatin C and mortality risk in the elderly: the health, aging, and body composition study. J Am Soc Nephrol. 2006; 17: 254-261.
16. Yanagisawa N., Ando M., Tsuchiya K., Nitta K. HIV-infected men with elevated level of serum cystatin C have a high likelihood of developing cancers. J Antivir Antiretrovir. 2012; 4: 38-42.
17. Yanagisawa N, Ando M, Tsuchiya K, Nitta K. Impact of cystatin C elevation and albuminuria on probability of adverse outcomes in HIV-infected men receiving HAART. Clin Nephrol. 2013; 79:362-369.
18. Köttgen A., Selvin E., Stevens L.A. et al. Serum cystatin C in the United States: The Third National Health and Nutrition Examination Survey (NHANES III). Am J Kidney Dis. 2008; 51: 385-394.
19. Gagneux-Brunon A., Mariat C., Delanaye P. Cystatin C in HIV-infected patients: Promising but not yet ready for prime time. Nephrol. Dial. Transplant. Off. Publ. Eur. Dial. Transpl. Assoc.-Eur. Ren. Assoc. 2012; 27: 1305-1313.
20. Odden M.C., Scherzer R., Bacchetti P. et al. Cystatin C level as a marker of kidney function in human immunodeficiency virus infection: the FRAM study. Arch Intern Med. 2007; 167: 2213-2219.
21. Knight E.L., Verhave J.C., Spiegelman D. et al. Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement. Kidney Int. 2004; 65: 1416-1421.
22. Levey A.S., Stevens L.A. Estimating GFR Using the CKD Epidemiology Collaboration (CKD-EPI) Creatinine Equation: More Accurate GFR Estimates, Lower CKD Prevalence Estimates, and Better Risk Predictions. Am. J. Kidney Dis. Off. J. Natl. Kidney Found. 2010; 55:622-627.
23. Cockcroft D.W., Gault M.H. Prediction of creatinine clearance from serum creatinine. Nephron. 1976; 16:31-41.
24. Diana N.E., Naicker S. Update on current management of chronic kidney disease in patients with HIV infection. Int J Nephrol Renovasc Dis. 2016; 9:22334.
25. Bonjoch A., Bayés B., Riba J. et al. Validation of estimated renal function measurements compared with the isotopic glomerular fltration rate in an HIV-infected cohort. Antiviral Res. 2010;88(3):347-54.
26. Yilma D., Abdissa A., Kæstel P. et al. Serum creatinine and estimated glomerular filtration rates in HIV positive and negative adults in Ethiopia. PLoS ONE. 2019; 14: e0211630.
27. Wyatt C.M., Hoover D.R., Shi Q. et al. Microalbuminuria is associated with all-cause and AIDS mortality in women with HIV infection. J Acquir Immune Defic Syndr. 2010; 55:73-77.
28. Choi A.I., Li Y., Deeks S.G., Grunfeld C. et al. Association between kidney function and albuminuria with cardiovascular events in HIV-infected persons. Circulation 2010; 121: 651-658.
29. Gravemann S., Brinkkoetter P.T., Vehreschild J.J. et al. Low-grade proteinuria is highly prevalent in HIV-positive patients on antiretroviral treatment. AIDS. 2014; 28: 1783-1789.
30. Ekrikpo U.E., Kengne A.P., Bello A.K. et al. Chronic kidney disease in the global adult HIV-infected population: A systematic review and meta-analysis. PLoS One. 2018; 13(4):e0195443.
31. Calza L., Sachs M., Colangeli V. et al. Prevalence of chronic kidney disease among HIV-1-infected patients receiving a combination antiretroviral therapy. Clin Exp Nephrol. 2019; 23: 1272-1279.
32. Verma B., Singh A. Clinical spectrum of renal disease in hospitalized HIV/AIDS patients: A teaching hospital experience. J Family Med Prim Care. 2019; 8:886-891.
33. Kooij K.W., Vogt L., Wit F. et al. Higher prevalence and faster progression of chronic kidney disease in human immunodeficiency virus-infected middle-aged individuals compared with human immunodeficiency virus-uninfected controls. J Infect Dis. 2017; 216:622-631.
34. Kim E.J., Ahn J.Y., Kim Y.J. et al. The prevalence and risk factors of renal insufficiency among Korean HIV-infected patients: the Korea HIV/AIDS Cohort Study. Infect Chemother. 2017; 49:194-204.
35. Hsieh M.H., Lu P.L., Kuo M.C. et al. Prevalence of and associated factors with chronic kidney disease in human immunodeficiency virus-infected patients in Taiwan. J Microbiol Immunol Infect. 2015; 48:256-262.
36. Nishijima T., Kawasaki Y., Mutoh Y. et al. Prevalence and factors associated with chronic kidney disease and end-stage renal disease in HIV-1-infected Asian patients in Tokyo. Sci Rep. 2017; 7:145-65.
37. Trivedi H., Vanikar A., Patel H. et al. High prevalence of chronic kidney disease in a semi-urban population of Western India. Clin Kidney J. 2016; 9:438-443.
38. Santiago P., Grinsztejn B., Friedman R.K. et al. Screening for decreased glomerular filtration rate and associated risk factors in a cohort of HIV infected patients in a middle-income country. PLoS One. 2014; 9:e93748.
39. Ayokunle D.S., Olusegun O.T., Ademola A. et al. Prevalence of chronic kidney disease in newly diagnosed patients with Human immunodeficiency virus in Ilorin, Nigeria. J Bras Nefrol 2015; 37:177-184.
40. Glaser N., Phiri S., Bruckner T. et al. The prevalence of renal impairment in individuals seeking HIV testing in Urban Malawi. BMC Nephrol. 2016; 17:186.
41. Patrice H.M., Moussa O., François K.F. et al. Prevalence and associated factors of chronic kidney disease among patients infected with human immunodeficiency virus in Cameroon. Iran J Kidney Dis. 2018; 12(5):268-274.
42. Szczech L.A., Grunfeld С., Scherzer R. et al. Microalbuminuria in HIV infection. AIDS. -2007; 21(8): 1003-1009.
43. Cheung C.Y., Wong K.M., Lee M.P. et al. Prevalence of chronic kidney disease in Chinese HIV-infected patients. Nephrol Dial Transplant 2007; 22:3186-3190.
44. Ryom L., Kirk O., Lundgren J.D. et al. Advanced chronic kidney disease, end-stage renal disease and renal death among HIV-positive individuals in Europe. HIV Med. 2013; 14:503-508. DOI: 10.1111/hiv.12038
45. Yanagisawa N., Muramatsu T., Koibuchi T. et al. Prevalence of chronic kidney disease and poor diagnostic accuracy of dipstick proteinuria in human immunodeficiency virus infected individuals: a multicenter study in Japan. Open Forum Infect Dis. 2018; 5(10):ofy216.
46. Mocroft A., Kirk O., Gatell J. et al. Chronic renal failure among HIV-1-infected patients. AIDS 2007; 21: 1119-1127.
47. Fernando SK, Finkelstein FO, Moore BA, Weissman S. Prevalence of chronic kidney disease in an urban HIV infected population. Am J Med Sci. 2008; 335: 89-94.
48. Szczech L.A., Gange S.J., van der Horst C. et al. Predictors of proteinuria and renal failure among women with HIV infection. Kidney Int. 2002; 61:195-202. DOI:10.1046/j.1523-1755.2002.00094.x
49. Cao Y., Gong M., Han Y. et al. Prevalence and risk factors for chronic kidney disease among HIV-infected antiretroviral therapy-naive patients in mainland China: a multicenter cross-sectional study. Nephrology. (Carlton). 2013; 18:307-312.
50. Fulop T., Olivier J., Meador R.S. et al. Screening for chronic kidney disease in the ambulatory HIV population. Clin Nephrol. 2010; 73: 190-196.
51. Wyatt C.M., Winston J.A., Malvestutto C.D. et al. Chronic kidney disease in HIV infection: an urban epidemic. AIDS. 2007; 21:2101-2103. DOI: 10.1097/QAD.0b013e3282ef1bb4
52. Gardner L.I., Holmberg S.D., Williamson J.M. et al. Development of proteinuria or elevated serum creatinine and mortality in HIV infected women. J Acquir Immune Defic Syndr. 2003; 32:203-209.
53. Edwards J.K., Bygrave H., Van den Bergh R. et al. HIV with non-communicable diseases in primary care in Kibera, Nairobi, Kenya: characteristics and outcomes 2010-2013. Transactions of the Royal Society of Tropical Medicine and Hygiene. 2015; 109(7):440-46.
54. Kazancioğlu R. Risk factors for chronic kidney disease: An update. Kidney Int. Suppl. 2013; 3: 368-371.
55. Prakash J., Ganiger V., Prakash S. et al. Kidney disease in human immunodeficiency virus-seropositive patients: Absence of human immunodeficiency virus-associated nephropathy was a characteristic feature. Indian J Nephrol. 2017; 27:271-276.
56. Fabrizi F., Dixit V., Martin P., Messa P. Hepatitis C virus increases the risk of kidney disease among HIV-positive patients: Systematic review and meta-analysis. J Med Virol. 2016; 88: 487-497.
57. Гаджикулиева М. М. Хроническая болезнь почек у ВИЧ-инфицированных пациентов: распространенность и клинико-морфологическая характеристика. Дисс. на соискание уч. степени доктора мед. наук. 2013. М. с.283
58. Ющук, Н.Д., Гаджикулиева М.М., Мартынов Ю.В., Волгина Г.В. Распространенность поражения почек среди ВИЧ-инфицированных пациентов. Информационный бюллетень «Здоровье население и среда обитания». - 2011. - №3. - С. 12-15.
59. Гаджикулиева М.М., Ющук Н.Д., Волгина Г.В. и соавт. Распространенность и клинико-морфологическая характеристика поражений почек при ВИЧ-инфекции. Нефрология и диализ. - 2012. - Т. 14. - №1. - С. 31-40.
60. Centers for Disease Control and Prevention. Diagnoses of HIV infection in the United States and dependent areas, 2016. HIV Surveillance Report, 2016; 28:1-125.
61. Prevention CfDCa. HIV Among people aged 50 and over. 2017. Available at: https://www.cdc.gov/hiv/group/age/olderamericans/index.html.
62. Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. Kidney Int Suppl. 2012; 2:341-342. doi:10.1038/kisup.2012.50.
63. Yanagisawa N., Muramatsu T., Yamamoto Y. et al. Classification of human immunodeficiency virus-infected patients with chronic kidney disease using a combination of proteinuria and estimated glomerular filtration rate. Clin Exp Nephrol. 2014; 18(4):600-605.
64. Lucas G.M., Ross M.J., Stock P.G. et al. HIV Medicine Association of the Infectious Diseases Society of America. Clinical practice guideline for the management of chronic kidney disease in patients infected with HIV: 2014 update by the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis. 2014; 59(9):e96-138.
65. Wyatt C.M. Kidney disease and HIV infection. Top Antivir Med. 2017; 25(1):13-16.
66. Abraham A.G., Althoff K.N., Guaraldi G. et al. North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of the International Epidemiologic Databases to Evaluate AIDS (IeDEA). End-stage renal disease among HIV-infected adults in North America. Clin Infect Dis. 2015; 60:941-949.
67. Louis M., Cottenet J., Salmon-Rousseau A. et al. Prevalence and incidence of kidney diseases leading to hospital admission in people living with HIV in France: an observational nationwide study. BMJ Open. 2019;9(5):e029211.
68. Heron J.E., Bagnis C.I., Gracey D.M. Contemporary issues and new challenges in chronic kidney disease amongst people living with HIV. AIDS Res Ther. 2020; 17:11-24. doi: 10.1186/s12981-020-00266-3
69. Collaboration Antiretroviral Therapy Cohort. Survival of HIV positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies. Lancet HIV. 2017; 4:e349-e356356.
70. Barril G., Trullas J.C., Gonzalez-Parra E. et al. Prevalence of HIV-1infection in dialysis units in Spain and potential candidates for renal transplantation: results of a Spanish survey. Enfermedades infecciosas y microbiologia clinica. 2005; 23(6):335-339.
71. Trullas J.C., Barril G., Cofan F. et al. Prevalence and clinical characteristics of HIV type 1-infected patients receiving dialysis in Spain: results of a Spanish survey in 2006: GESIDA 48/05 study. AIDS research and human retroviruses. 2008; 24(10):1229-235.
72. Halle M.P., Takongue C., Kengne A.P. et al. Epidemiological profile of patients with end stage renal disease in a referral hospital in Cameroon. BMC nephrology. 2015; 16:59.
73. Xie Y., Bowe B., Mokdad A.H. et al. Analysis of the Global Burden of Disease study highlights the global, regional, and national trends of chronic kidney disease epidemiology from 1990 to 2016. Kidney Int. 2018; 94(3):567-581.
74. Dummer P.D., Limou S., Rosenberg A.Z. et al. APOL1 kidney disease risk variants: an evolving landscape. Seminars in nephrology. Amsterdam: Elsevier; 2015.
75. Collins A.J., Foley R.N., Chavers, B. et al. United States Renal Data System 2011 Annual Data Report: Atlas of chronic kidney disease & end-stage renal disease in the United States. Am. J. Kidney Dis. Off. J. Natl. Kidney Found. 2012; 59, A7.
76. Rosset S., Tzur S., Behar D.M. et al. The population genetics of chronic kidney disease: insights from the MYH9-APOL1 locus. Nature reviews. Nephrology. 2011; 7:313-326.
77. Freedman B.I., Limou S., Ma L., Kopp J.B. APOL1-associated nephropathy: a key contributor to racial disparities in CKD. Am J Kidney Dis. 2018; 72(5):S8-S16.
78. Papeta N., Kiryluk K., Patel A. et al. APOL1 Variants Increase Risk for FSGS and HIVAN but Not IgA Nephropathy. JASN. 2011; 22 (11):1991-1996.
79. Ulasi I.I., Tzur S., Wasser W.G. et al. High Population Frequencies of APOL1 Risk Variants Are Associated with Increased Prevalence of Non-Diabetic Chronic Kidney Disease in the Igbo People from South-Eastern Nigeria. Nephron Clinical Practice. 2013; 123(1-2):123- 128.
80. Dietrich LG, Barcelo C, Thorball CW. et al. Contribution of Genetic Background and Data Collection on Adverse Events of Anti-human Immunodeficiency Virus (HIV) Drugs (D:A:D) Clinical Risk Score to Chronic Kidney Disease in Swiss HIV-infected Persons With Normal Baseline Estimated Glomerular Filtration Rate. Clin Infect Dis. 2020; 70(5):890-897.
81. Ford N., Ball A., Baggaley R. et al. The WHO public health approach to HIV treatment and care: looking back and looking ahead. Lancet Infect Dis. 2017; doi: 10.1016/S1473-3099(17)30482-6.
82. Wearne N., Okpechi I.G. HIV-associated renal disease - an overview. Clin Nephrol. 2016; 86:41-47.
83. Mallipattu S.K., Salem F., Wyatt C.M. The changing epidemiology of HIV-related chronic kidney disease in the era of antiretroviral therapy. Kidney Int. 2014; 86:259-265.
84. Mocroft A., Kirk O., Reiss P. et al. Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients. AIDS (London, England). 2010; 24(11):1667-78.
85. Cristelli M.P., Cofaґn F., Rico N. et al. Estimation of renal function by CKD-EPI versus MDRD in a cohort of HIV-infected patients: A cross-sectional analysis. BMC Nephrology. 2017; 18:2-7
86. Bickel M., Marben W., Betz C. et al. End stage renal disease and dialysis in HIV-positive patients: observations from a long-term cohort study with a follow-up of 22 years. HIV Med. 2013; 14:127-135.
87. Ahuja T.S., Collinge N., Grady J. et al. Is dialysis modality a factor in survival of patients with ESRD and HIV-associated nephropathy? Am J Kidney Dis. 2003; 41:1060-1064.
88. Soleymanian T., Raman S., Shannaq F. et al. Survival and morbidity of HIV patients on hemodialysis and peritoneal dialysis: one center’s experience and review of the literature. Int Urol Nephrol. 2006; 38: 331-38.
89. Centers for Disease Control and Prevention. Preventing infections in dialysis setting guideline. Available at: https://www.cdc.gov/infectioncontrol/guidelines/dialysis/index.html. Accessed July 19, 2017.
90. Stock P.G., Barin B., Murphy B. et al. Outcomes of kidney transplantation in HIV infected recipients. N Engl J Med. 2010; 363:2004-14.
91. Sawinski D., Bloom R.D. Current status of kidney transplantation in HIV-infected patients. Curr Opin Nephrol Hypertens. 2014; 23:619-24.
92. AIDSinfo. Guidelines for the use of Antiretroviral Agents in HIV-1 infected Adults and Adolescents 2016 16th November 2016. https://aidsinfo.nih.gov/contentfiles/lvguidelines/AA_Recommendations.pdf.
93. Gueler A., Moser A., Calmy A. et al. Life expectancy in HIV-positive persons in Switzerland: Matched comparison with general population. AIDS Lond. Engl. 2017; 31:427-436.
94. Coquet I., Pavie J., Palmer P. et al. Survival trends in critically ill HIV-infected patients in the highly active antiretroviral therapy era. Crit Care. 2010; 14, R107.
95. Mallipattu S.K., Salem F., Wyatt C.M. The changing epidemiology of HIV-related chronic kidney disease in the era of antiretroviral therapy. Kidney Int. 2014; 86(2):259-265.
96. Sabin C.A. Do people with HIV infection have a normal life expectancy in the era of combination antiretroviral therapy? BMC Med. 2013; 11:251.
97. Alfano G., Cappelli G., Fontana F. et al. Kidney Disease in HIV Infection. J. Clin. Med. 2019; 8(8):1254 (1-9). doi:10.3390/jcm8081254
98. Swanepoel C.R., Atta M.G., D’Agati V.D. et al. Kidney disease in the setting of HIV infection: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney International. 2018; 93:545-559. https://doi.org/10.1016/j.kint.2017.11.007
99. Nobakht E., Cohen S.D., Rosenberg A.Z. et al. HIV-associated immune complex kidney disease. Nat Rev Nephrol. 2016; 12:291-300.
100. Wyatt C.M., Morgello S., Katz-Malamed R. et al. The spectrum of kidney disease in patients with AIDS in the era of antiretroviral therapy. Kidney Int. 2009; 75:428-34.
101. Campos P., Ortiz A., Soto K. HIV and kidney diseases: 35 years of history and consequences. Clin Kidney J. 2016; 9: 772-81.
102. Booth J.W., Hamzah L., Jose S. et al. Clinical characteristics and outcomes of HIV-associated immune complex kidney disease. Nephrol Dial Transplant. 2016; 31:2099-107.
103. Sury K., Perazella M.A. The changing face of human immunodeficiency virus-mediated kidney disease. Adv Chronic Kidney Dis. 2019; 26(3):185-97.
104. Cohen S.D., Kopp J.B., Kimmel P.L. Kidney Diseases Associated with Human Immunodeficiency Virus Infection. N Engl J Med. 2017; 377:2363-74. DOI: 10.1056/NEJMra1508467
105. Bendapudi P.K., Upadhyay V., Sun L. et al. Clinical scoring Systems in Thrombotic Microangiopathies. Semin Thromb Hemost. 2017; 43(5):540-8.
106. Joly B.S., Coppo P., Veyradier A. Thrombotic thrombocytopenic purpura. Blood. 2017; 129 (21):2836-46.
107. Kappler S., Ronan-Bentle S., Graham A. Thrombotic Microangiopathies (TTP, HUS, HELLP). Hematol Oncol Clin North Am. 2017; 31(6):1081-103.
108. Sadler J.E. What’s new in the diagnosis and pathophysiology of thrombotic thrombocytopenic purpura. Hematology Am Soc Hematol Educ Program. 2015; 2015:631-36.
109. Saab K.R., Elhadad S., Copertino D., Laurence J. Thrombotic Microangiopathy in the setting of HIV infection: a case report and review of the differential diagnosis and therapy. AIDS Patient Care STDs. 2016; 30 (8):359-64.
110. Sayani F.A., Abrams C.S. How I treat refractory thrombotic thrombocytopenic purpura. Blood. 2015; 125(25):3860-67.
111. Lucas S., Nelson A.M. HIV and the spectrum of human disease. J Pathol. 2015; 235, 229-241.
112. Wearne N., Swanepoel C.R., Boulle A. et al. The spectrum of renal histologies seen in HIV with outcomes, prognostic indicators and clinical correlations. Nephrol Dial Transplant. 2012; 27:4109-4118.
113. Lescure F-X., Fellahi S., Pialoux G. et al. Prevalence of tubulopathy and association with renal function loss in HIV-infected patients. Nephrol Dial Transplant. 2020; 35: 607-615.
114. Fox C., Walker-Bone K. Evolving spectrum of HIV-associated rheumatic syndromes. Best Pract Res Clin Rheumatol. 2015; 29:244-258.
115. Гаджикулиева М.М., Волгина Г.В., Пархоменко Ю.Г., Тишкевич О.А. Поражение почек при ВИЧ-инфекции по данным аутопсии. Журн. Нефрология и диализ. 2013; 15(4):309-310.
116. Kumar N., Perazella M.A. Differentiating HIV-associated nephropathy from antiretroviral drug-induced nephropathy: a clinical challenge. Curr HIV/AIDS Rep. 2014; 11:202-211.
117. Rodriguez-Penney A.T., Iudicello J.E., Riggs P.K. et al. Co-morbidities in persons infected with HIV: increased burden with older age and negative effects on health-related quality of life. AIDS Patient Care STDS. 2013; 27:5-16.
118. Lake J.E., Currier J.S. Metabolic disease in HIV infection. Lancet Infect Dis. 2013; 13: 964-975.
119. Calvo M., Martinez E. Update on metabolic issues in HIV patients. Curr Opin HIV AIDS. 2014; 9: 332-39.
120. Wu P.-Y., Hung C.-C., Liu W.-C. et al. Metabolic syndrome among HIV-infected Taiwanese patients in the era of highly active antiretroviral therapy: Prevalence and associated factors. J. Antimicrob. Chemother. 2012; 67:1001-1009.
121. Barnighausen T. The HIV treatment cascade and antiretroviral impact in different populations. Curr Opin HIV AIDS. 2015; 10:391-94.
122. Lundgren J., Mocroft A., Ryom L. Contemporary protease inhibitors and cardiovascular risk. Curr. Opin. Infect. Dis. 2018; 31:8-13.
123. Wong C., Gange S.J., Buchacz K. et al. First occurrence of diabetes, chronic kidney disease, and hypertension among North American HIV-infected adults, 2000-2013. Clin Infect Dis. 2017; 64: 459-467.
124. Llibre J.M., Hill. A. Abacavir and cardiovascular disease: A critical look at the data. Antiviral Res. 2016; 132: 116-121.
125. Ryom L., Lundgren J.D., El-Sadr et al. Cardiovascular disease and use of contemporary protease inhibitors: The D:A:D international prospective multicohort study. Lancet HIV. 2018; 5: e291-e300.
126. Gutierrez J., Albuquerque A.L.A., Falzon L. HIV infection as vascular risk: a systematic review of the literature and meta-analysis. PLoS ONE. 2017; 12(5):e0176686.
127. Idris N.S., Grobbee D.E., Burgner D. et al. Effects of paediatric HIV infection on childhood vasculature. Eur Heart J. 2016; 37(48):3610-3616.
128. Szczech L.A., Gupta S.K., Habash R. et al. The clinical epidemiology and course of the spectrum of renal diseases associated with HIV infection. Kidney Int. 2004; 66:1145-1152.
129. Achhra A.C., Mocroft A., Ross M.J. et al. Kidney disease in antiretroviral-naive HIV-positive adults with high CD4 counts: prevalence and predictors of kidney disease at enrolment in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial. HIV Med. 2015; 16 (Suppl: 1):55-63.
130. Menezes A.M., Torelly J. Jr., Real L. et al. Prevalence and risk factors associated to chronic kidney disease in HIV-infected patients on HAART and undetectable viral load in Brazil. PLoS One. 2011; 6: e26042.
131. World Health Organization (2019) Global Health Sector Strategy on HIV, 2016-2021: Key Facts on HIV/AIDS. https://www.who.int/fr/news-room/fact-sheets/detail/hiv-aids
132. Ryom L., Mocroft A., Kirk O. et al. Predictors of advanced chronic kidney disease and end-stage renal disease in HIV-positive persons. AIDS. 2014; 28:187-199.
133. Lucas G.M., Eustace J.A., Sozio S. et al. Highly active antiretroviral therapy and the incidence of HIV-1-associated nephropathy: a 12-year cohort study. AIDS. 2004; 18: 541-546.
134. Ross M.J., Klotman P.E. HIV-associated nephropathy. AIDS. 2004; 18: 1089-1099.
135. Ying R., Granich R.M., Gupta S., Williams B.G. CD4 cell count: declining value for antiretroviral therapy eligibility. Clin Infect Dis. 2016; 62(8):1022-1028.
136. Гаджикулиева М.М., Ющук Н.Д., Мартынов Ю.В., Волгина Г.В. Частота маркеров и факторы риска повреждения почек при ВИЧ-инфекции. Информационный бюллетень «Здоровье население и среда обитания». 2011. - №6. - С. 33-35.
137. Tsui J., Vittinghoff E., Anastos K. et al. Hepatitis C seropositivity and kidney function decline among women with HIV: data from the Women's Interagency HIV Study. Am J Kidney Dis. 2009; 54:43-50.
138. Huang J.F., Chuang W.L., Dai C.Y. et al. Viral hepatitis and proteinuria in an area endemic for hepatitis B and C infections: another chain of link? J Intern Med. 2006; 260:255-262.
139. Lee J.J., Lin M.Y., Yang Y.H. et al. Association of hepatitis C and B virus infection with CKD in an endemic area in Taiwan: a cross-sectional study. Am J Kidney Dis. 2010; 56:23-31.
140. Wyatt C.M., Malvestutto C., Coca S.G. et al. The impact of hepatitis C virus coinfection on HIV-related kidney disease: a systematic review and meta-analysis. AIDS. 2008; 22:1799-1807.
141. Kupin W.L. Viral-associated GN: hepatitis C and HIV. Clin J Am Soc Nephrol. 2017;12(8):1337-1342.
142. George E., Nadkarni G.N., Estrella M.M. et al. The Impact of Hepatitis C Coinfection on Kidney Disease Related to Human Immunodeficiency Virus (HIV): A Biopsy Study. Medicine (Baltimore). 2011; 90:289-295.
143. Bagheri Amiri F., Mostafavi E., Mirzazadeh A. HIV, HBV and HCV coinfection prevalence in Iran-a systematic review and meta-analysis. PLoS ONE. 2016;11(3):e0151946.
144. McGuire B.M., Julian B.A., Bynon J.S.J. et al. Brief communication: Glomerulonephritis in patients with hepatitis C cirrhosis undergoing liver transplantation. Ann Intern Med. 2006; 144:735-741.
145. Rossi С., Raboud J., Walmsley S. et al. and the Canadian Observational Cohort (CANOC) Collaboration. Hepatitis C co-infection is associated with an increased risk of incident chronic kidney disease in HIV-infected patients initiating combination antiretroviral therapy. BMC Infectious Diseases. 2017; 17:246 (1-10). DOI 10.1186/s12879-017-2350-8
146. Peters L., Grint D., Lundgren J.D. et al. HCV viremia increases the incidence of chronic kidney disease in HIV-infected patients. AIDS. 2012; 26(15):1917-26.
147. Lucas G.M., Jing Y., Sulkowski M. et al. Hepatitis C viremia and the risk of chronic kidney disease in HIV-infected individuals. J Infect Dis. 2013; 208:1240-1249.
148. Mocroft A., Neuhaus J., Peters L. et al. INSIGHT SMART, ESPRIT Study Groups. Hepatitis B and C Co-Infection Are Independent Predictors of Progressive Kidney Disease in HIV-Positive, Antiretroviral-Treated Adults. PLoS One. 2012; 7(7): e40245. doi: 10.1371/journal.pone.0040245
149. Gupta S.K., Eustace J.A., Winston J.A. et al. Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis. 2005; 40:1559-1585.
150. Shen T.C., Huang K.Y., Chao C.H. et al. The risk of chronic kidney disease in tuberculosis: a population-based cohort study. QJM. 2015; 108:397-403. [PubMed: 25352683]
151. Wen Y.K., Chen M.L. Crescentic glomerulonephritis associated with miliary tuberculosis. Clin Nephrol. 2009; 71:310-313.
152. Jha V., Prasad N. CKD and infectious diseases in Asia Pacific: challenges and opportunities. Am J Kidney Dis. 2016; 68:148-160.
153. Viglietti D., Verine J., De Castro N. et al. Chronic interstitial nephritis in an HIV type-1-infected patient receiving ritonavir-boosted atazanavir. Antivir Ther. 2011; 16:119-121.
154. Kanzaki G., Tsuboi N., Miyazaki Y. et al. Diffuse tubulointerstitial nephritis accompanied by renal crystal formation in an HIV-infected patient undergoing highly active antiretroviral therapy. Intern Med 2012; 51: 1543-1548.
155. Cooper R.D., Wiebe N., Smith N. et al. Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients. Clin Infect Dis. 2010; 51:496-505
156. De Wit S., Sabin C.A., Weber R. et al. Incidence and risk factors for new-onset diabetes in HIV-infected patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study. Diabetes Care. 2008; 31(6):1224-1229.
157. Seaberg E.C., Munoz A., Lu M. et al. Association between highly active antiretroviral therapy and hypertension in a large cohort of men followed from 1984 to 2003. AIDS. 2005;19(9):953- 960.
158. Bergersen B.M., Sandvik L., Dunlop O. et al. Prevalence of hypertension in HIV-positive patients on highly active retroviral therapy (HAART) compared with HAART-naive and HIV-negative controls: Results from a Norwegian study of 721 patients. Eur J Clin Microbiol Infect Dis. 2003; 22: 731-736.
159. Crane H.M., Van Rompaey S.E., Kitahata M.M. Antiretroviral medications associated with elevated blood pressure among patients receiving highly active antiretroviral therapy. AIDS 2006; 20:1019-1026.
160. Chow F.C. HIV infection, vascular disease, and stroke. Semin Neurol. 2014; 34(1):35-46. doi: 10.1055/s-0034-1372341.
161. Gameiro J., Fonseca J.A., Jorge S., Lopes J.A. Acute kidney injury in HIV infected patients: a critical review. HIV Med. 2019; 20(2):77-87.
162. Lopes J.A., Melo M.J., Raimundo M., Fragoso A., Antunes F. Long-term risk of mortality for acute kidney injury in HIV-infected patients: a cohort analysis. BMC Nephrol. 2013; 14(1):32. DOI: 10.1186/1471-2369-14-32
163. Ibrahim F., Naftalin C., Cheserem E. et al. Immunodeficiency and renal impairment are risk factors for ВИЧ-associated acute renal failure. AIDS. 2010; 24: 2239-2244.
164. Hsu C.Y., Ordonez J.D., Chertow G.M. et al. The risk of acute renal failure in patients with chronic kidney disease. // Kidney Int. 2008; 74(1): 101-107.
165. Chawla L.S., Eggers P.W., Star R.A., Kimmel P.L. Acute kidney injury and chronic kidney disease as interconnected syndromes. N Engl J Med 2014; 371:58-66.
166. Choi A.I., Li Y., Parikh C. et al. Long-term clinical consequences of acute kidney injury in the HIV infected. Kidney Int. 2010; 78(5):478-485. [PubMed: 20520594]
167. Abraham A.G., Althoff K.N., Jing Y. et al. End-stage renal disease among HIV-infected adults in North America. Clin Infect Dis. 2015; 60:941-949. [PubMed: 25409471]
168. Jha V., Garcia-Garcia G., Iseki K. et al. Chronic kidney disease: global dimension and perspectives. Lancet. 2013; 382:260-272. [PubMed: 23727169]
169. Wong C., Gange S.J., Buchacz K. et al. North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD): First occurrence of diabetes, chronic kidney disease, and hypertension among North American HIV-infected adults, 2000-2013. Clin Infect Dis. 2017; 64:459-467. [PubMed: 28172581]
170. Jotwani V., Li Y., Grunfeld C. et al. Risk factors for ESRD in HIV-infected individuals: traditional and HIV-related factors. Am. J. Kidney Dis. 2012; 59:628-635.
171. Ryom L., Mocroft A., Kirk O. et al. Predictors of advanced chronic kidney disease and end-stage renal disease in HIV-positive persons. AIDS. 2014; 28:187-199. [PMID: 24361680 DOI: 10.1097/QAD.0000000000000042]
172. Feinstein M.J., Hsue P.Y., Benjamin L.A. et al. Characteristics, Prevention, and Management of Cardiovascular Disease in People Living with HIV: A Scientific Statement from the American Heart Association. Circulation. 2019; 140: e98-e124.
173. Flandre P., Pugliese P., Cuzin L. et al. Risk Factors of Chronic Kidney Disease in HIV-Infected Patients. Clin J Am Soc Nephrology. 2011; 6: 1700-1707. https://doi.org/10.2215/CJN.09191010
174. Hsieh, M.-H., Lu P.L., Kuo M.C. et al. Prevalence of and Associated Factors with Chronic Kidney Disease in Human Immunodeficiency Virus-Infected Patients in Taiwan. Journal of Microbiology, Immunology and Infection. 2015; 48(3):256-262. https://doi.org/10.1016/j.jmii.2013.08.013
175. Freiberg M.S., Chang C.C., Kuller L.H. et al. HIV infection and the risk of acute myocardial infarction. JAMA Intern Med. 2013; 173:614-22.
176. Grinspoon S.K. Cardiovascular Disease in HIV: Traditional and Nontraditional Risk Factors. Top Antivir Med. 2014; 22:676-679.
177. Deeks S.G. HIV infection, inflammation, immunosenescence, and aging. Annu Rev Med. 2011; 62:141-55.
178. Martin J., Volberding P. HIV and premature aging: A field still in its infancy. Ann Intern Med. 2010; 153:477-9.
179. Angelovich T.A., Hearps A.C., Maisa A. et al. Viremic and Virologically Suppressed HIV Infection Increases Age-Related Changes to Monocyte Activation Equivalent to 12 and 4 Years of Aging, Respectively. J Acquir Immune Defic Syndr. 2015; 69:11-17.
180. Pathai S., Bajillan H., Landay A.L., High K.P. Is HIV a model of accelerated or accentuated aging? J Gerontol A Biol Sci Med Sci. 2014; 69:833-42.
181. Althoff K.N., McGinnis K.A., Wyatt C.M. et al. Comparison of risk and age at diagnosis of myocardial infarction, end-stage renal disease, and non-AIDS-defining cancer in HIV-infected versus uninfected adults. Clin Infect Dis. 2015; 60:627-38.
182. Capeau J. Premature Aging and Premature Age-Related Comorbidities in HIV-Infected Patients: Facts and Hypotheses. Clin Infect Dis. 2011; 53:1127-9.
183. Gueler A., Moser A., Calmy A. et al. Swiss HIV Cohort Study, Swiss National Cohort. Life expectancy in HIV-positive persons in Switzerland: Matched comparison with general population. AIDS Lond. Engl. 2017; 31: 427-436. doi: 10.1097/QAD.0000000000001335.
184. Schouten J., Wit F.W., Stolte I.G. et al. Cross-sectional comparison of the prevalence of age associated comorbidities and their risk factors between HIV-infected and uninfected individuals: the AGEhIV cohort study. Clin Infect Dis. 2014; 59:1787-97.
185. Pathai S., Bajillan H., Landay A.L., High K.P. Is HIV a model of accelerated or accentuated aging? J Gerontol A Biol Sci Med Sci. 2014; 69:833-42.
186. High K.P., Brennan-Ing M., Clifford D.B. et al. HIV and aging: state of knowledge and areas of critical need for research.
187. A report to the NIH Office of AIDS Research by the HIV and Aging Working Group. J Acquir Immune Defic Syndr 2012; 60 (Suppl 1):S1-S18.
188. Lescure F-X., Fellahi S., Pialoux G. et al. Prevalence of tubulopathy and association with renal function loss in HIV-infected patients. Nephrol Dial Transplant. 2020; 35: 607-615.
189. Althoff K.N., Justice A.C., Gange S.J. et al. Virologic and immunologic response to HAART, by age and regimen class. AIDS. 2010; 24:2469-79.
190. Sabin C.A., Smith C.J., d'Arminio Monforte A. et al. Response to combination antiretroviral therapy: variation by age. AIDS. 2008; 22:1463-73.
191. Viard J.P., Mocroft A., Chiesi A. et al. Influence of age on CD4 cell recovery in human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy:evidence from the EuroSIDA study. J Infect Dis. 2001; 183:1290-4.
192. Silverberg M.J., Leyden W., Horberg M.A. et al. Older age and the response to and tolerability of antiretroviral therapy. Arch Intern Med. 2007; 167:684-91.
193. Centers for Disease Control and Prevention. Monitoring selected national HIV prevention and care objectives by using HIV surveillance data-United States and 6 U.S. dependent areas, 2015. HIV Surveillance Supplemental Report. 2017; 22(2):1-63. Published July 2017.
194. Mocroft A., Lundgren J.D., Ross M. et al. D:A:D study group; Royal Free Hospital Clinic Cohort; INSIGHT study group; SMART study group; ESPRIT study group. Development and validation of a risk score for chronic kidney disease in HIV infection using prospective cohort data from the D:A:D study. PLoS Med. 2015; 12: e1001809.
195. El-Sadr W.M., Lundgren J., Neaton J.D. et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med. 2006; 355:2283-96.
196. Deeks S.G., Phillips A.N. HIV infection, antiretroviral treatment, ageing, and non-AIDS related morbidity. BMJ. 2009; 338: a3172.
197. Jotwani V., Li Y., Grunfeld C., Choi A.I., Shlipak M.G. Risk Factors for ESRD in HIV-Infected Individuals: Traditional and HIV-Related Factors. AJKD. 2012; 59(5):628-635.
198. Swanepoe C.R., Atta M.G., D’Agati V.D. et al. and for Conference Participants Kidney disease in the setting of HIV infection: Conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2018; 93(3):545-559. doi:10.1016/j.kint.2017.11.007.
199. Ando M., Yanagisawa N., Ajisawa A. et al. A simple model for predicting incidence of chronic kidney disease in HIV infected patients. Clin Exp Nephrol 2011; 15: 242-247. DOI: 10.1007/s10157-010-0393-x
200. Scherzer R., Gandhi M., Estrella M.M. et al. A chronic kidney disease risk score to determine tenofovir safety in a prospective cohort of HIV-positive male veterans. AIDS. 2014; 28: 1289-1295. DOI:10.1097/QAD.0000000000000258

Другие статьи по теме

• Нефротоксические эффекты высокоактивной антиретровирусной терапии (Обзор литературы)
• Хроническая почечная недостаточность (хроническая болезнь почек 3-5 стадии) у детей Воронежского региона
• Смешанная криоглобулинемия у пациентов с ВИЧ или ВИЧ/ВГС и признаками хронической болезни почек
• COVID-19 у пациентов с поздними стадиями диабетической болезни почек: потребность в гемодиализе de novo как один из предикторов неблагоприятного исхода